Literature DB >> 10904422

Link between Helicobacter pylori infection and idiopathic parkinsonism.

S M Dobbs1, R J Dobbs, C Weller, A Charlett.   

Abstract

The conventional concept for an environmental cause of idiopathic parkinsonism is an insult (e.g. neurotoxin or encephalitis), superimposed on age-related attrition of nigral dopaminergic neurons, and temporally remote from neurological diagnosis. To the contrary, we describe the fit of Helicobacter pylori. This commonest of known bacterial infections, usually acquired in childhood, persists, and has been linked with peptic ulcer/non-ulcer dyspepsia, immunosuppression and autoimmunity. Acquired immunosuppression, predisposing to auto-immunity, is assessed as a model for the pathogenesis of parkinsonism and parkinsonian-like attributes of ageing. Eradication of a trigger has potential to change the approach to parkinsonism, just as it did to peptic ulcer. The tenet of inevitable age-related attrition of dopaminergic neurons may also require revision. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10904422     DOI: 10.1054/mehy.2000.1110

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  16 in total

Review 1.  Helicobacter pylori and neurological diseases: Married by the laws of inflammation.

Authors:  Lourdes Alvarez-Arellano; Carmen Maldonado-Bernal
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 2.  Helicobacter pylori infection and drugs malabsorption.

Authors:  Edith Lahner; Camilla Virili; Maria Giulia Santaguida; Bruno Annibale; Marco Centanni
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype.

Authors:  R C Tabata; J M B Wilson; P Ly; P Zwiegers; D Kwok; J M Van Kampen; N Cashman; C A Shaw
Journal:  Neuromolecular Med       Date:  2008-01-15       Impact factor: 3.843

Review 4.  Brain-gut-microbiota axis in Parkinson's disease.

Authors:  Agata Mulak; Bruno Bonaz
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

Review 5.  The role of innate and adaptive immunity in Parkinson's disease.

Authors:  George T Kannarkat; Jeremy M Boss; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

6.  Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism.

Authors:  Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Ingvar T Bjarnason; Andrew J Lawson; Darren Letley; Lucy Harbin; Ashley B Price; Mohammad A A Ibrahim; Norman L Oxlade; James Bowthorpe; Daniel Leckstroem; Cori Smee; J Malcolm Plant; Dale W Peterson
Journal:  Helicobacter       Date:  2010-08       Impact factor: 5.753

7.  Augmentation of Autoantibodies by Helicobacter pylori in Parkinson's Disease Patients May Be Linked to Greater Severity.

Authors:  Gunasekaran Suwarnalata; Ai Huey Tan; Hidayah Isa; Ranganath Gudimella; Arif Anwar; Mun Fai Loke; Sanjiv Mahadeva; Shen-Yang Lim; Jamuna Vadivelu
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 8.  Association between Parkinson's Disease and Helicobacter Pylori.

Authors:  Gülşah Çamcı; Sıdıka Oğuz
Journal:  J Clin Neurol       Date:  2016-02-26       Impact factor: 3.077

9.  Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation.

Authors:  Aisha D Augustin; André Charlett; Clive Weller; Sylvia M Dobbs; David Taylor; Ingvar Bjarnason; R John Dobbs
Journal:  Br J Clin Pharmacol       Date:  2016-05-21       Impact factor: 4.335

10.  Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice.

Authors:  Sara Ekmark-Lewén; Veronica Lindström; Astrid Gumucio; Elisabeth Ihse; Anish Behere; Philipp J Kahle; Eva Nordström; Maria Eriksson; Anna Erlandsson; Joakim Bergström; Martin Ingelsson
Journal:  Brain Behav       Date:  2018-02-04       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.